Navigation Links
Investigation Findings, Corroborated by Empirical Evidence of the,Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine,for Hundreds of Years, Support the Use of Schisandrin B in the,Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation, Inc. (Pink Sheets:MTPM), releases the results of a research paper where Professor Dr. Robert Ko published the beneficial effects of Schisandrin B, the precursor of (-) Schisandrin B - a novel discovery by Dr. Ko - on Ischemic Heart Disease.

In a research paper entitled "SCHISANDRIN B PROTECTS AGAINST MYOCARDIAL ISCHEMIA-REPERFUSION INJURY BY ENHANCING MYOCARDIAL GLUTATHIONE ANTIOXIDANT STATUS"; Yim and Ko; Molecular and Cellular Biochemistry 1999; 196: 151-156, Professor Dr. Robert Ko published the beneficial effects of Schisandrin B, the precursor of (-) Schisandrin B - a novel discovery by Dr. Ko - on Ischemic Heart Disease.

Ischemic heart disease (IHD) is the major cause of death in most industrialized countries. Following the removal of blood clot in the coronary artery, reperfusion of the previously blood-deprived myocardium can cause additional tissue damage. This phenomenon of ischemia-reperfusion (I-R) injury is an important cause of heart dysfunction and eventually death in patients suffering from IHD. Agents that offer heart protection against I-R injury is therefore of great therapeutic value in the prevention and treatment of IHD.

Schisandrin B, an active ingredient from Schisandra Berry, a well-known cardio-tonic in traditional Chinese medicine, has been shown to possess antioxidant properties. This investigation aims to examine whether Schisandrin B can protect against I-R injury in the heart. The results demonstrate for the first time cardio-protection afforded by Schisandrin B against I-R injury BY ENHANCING MYOCARDIAL GLUTATHIONE ANTIOXIDANT STATUS. In contrast, Dimethyl Diphenyl Bicarboxylate (DDB), an anti-hepatitis drug with a similar chemical structure to Schisandrin B, does not produce any cardio-protective effect or enhance tissue antioxidant status. This bespeaks much of the unique ability of Schisandrin B to e nhance the free radical scavenging capacity of the heart, thereby protecting against I-R injury.

The finding, which is corroborated by empirical evidence of the Schisandra berry as cardio-tonic in Traditional Chinese Medicine for hundreds of years, supports the use of Schisandrin B in the prevention and treatment of IHD.

Since the publication of this finding, Dr. Ko has identified an isomer of Schisandrin B, (-) Schisandrin B, a novel discovery, which possesses a more potent pharmacological profile than that of Schisandrin B. Patented use of this newly discovered compound, (-) Schisandrin B, for the prevention and treatment of Ischemic Heart Disease has been applied for with the US Patent and Trademark Office.

For a copy of this research report, please contact the publisher, Molecular and Cellular Biochemistry.

About the Company

MitoPharm Corporation is a biotechnology company in the research & development, marketing and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly discovered compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST"). MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active. www.mitopharm.com

At HKUST, scientific studies have identified biochemical actions of MitoPharm's key Compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the Compound f rom other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain. www.ust.hk.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.

Contact

Mogul IR
Robert Adams, 713-401-9333 (Investor Relations)
radams@mogulir.com


'"/>




Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):